Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Hematologic Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Kidney Neoplasms 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Breast Cancer, Familial 1

Interventions

Gemcitabine 18pembrolizumab 16Cisplatin 16Nivolumab 15atezolizumab 11durvalumab 9Specimen Handling 9Magnetic Resonance Spectroscopy 9Cystectomy 8Carboplatin 7Ipilimumab 6Fluorouracil 6avelumab 5Mitomycin 5sacituzumab govitecan 4erdafitinib 4enfortumab vedotin 4Surgical Procedures, Operative 4Immunoglobulin G 4Disulfides 4Biopsy 4tremelimumab 3cabozantinib 3Transurethral Resection of Bladder 3Surveys and Questionnaires 3Radiation 3Platinum 3Paclitaxel 3Leucovorin 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urinary Bladder Neoplasms × Health Promotion × Clear all
NCT05056077 2026-06-02

TTBF

University of California, San Francisco

Phase NA Active not recruiting
353 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Kidney Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡